Evaluation of a Drug Combination for Treatment of Bacterial Urinary Infection in Patients with E. coli Urinary Tract Infection

The primary objective of the study is to evaluate the efficacy of a treatment for **bacterial urinary infection** caused by **E. coli**. This is clinically relevant as **E. coli** is a common pathogen responsible for urinary tract infections, which can lead to significant morbidity if not effectively treated. The study aims to provide insights into the effectiveness of the treatment in reducing infection rates and improving patient outcomes.

The clinical trial focuses on individuals diagnosed with **bacterial urinary infection**. The study population includes both male and female participants, with an age range spanning from 18 to 65 years. The trial involves a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants were selected based on criteria that ensure a representative sample of the general population affected by this condition. Lifestyle factors such as diet, physical activity, and habits were considered, although specific details are not disclosed. The trial aims to gather comprehensive data on this demographic to better understand the condition and potential treatments.

The clinical trial is designed to evaluate the safety and efficacy of a treatment for **bacterial urinary infection**. This study is a Phase 1 trial, which typically involves a small number of participants to assess the safety profile of the investigational treatment. The trial is structured as a randomized, double-blind, controlled study to ensure unbiased results and to compare the investigational treatment against a placebo or standard treatment. The estimated recruitment start date is March 1, 2024, with an anticipated end date of May 31, 2025, indicating a total trial duration of approximately 15 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment, including medical history review and laboratory tests. Following successful screening, participants will be randomized into treatment groups. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess treatment efficacy, and record any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study.

The end-of-study visit will occur after the final treatment cycle, where a thorough evaluation will be conducted to gather final safety and efficacy data. The expected length of participant involvement is contingent upon the study's schedule and individual response to treatment, but it is generally expected to last until the end of the trial. Participants may be withdrawn from the study early if they experience significant adverse effects, fail to comply with study procedures, or choose to withdraw consent. The trial's design and procedures are meticulously planned to ensure the collection of reliable data while prioritizing participant safety and well-being.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is available from the provided data. Consequently, a detailed description of the experimental treatment cannot be provided.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Therefore, a description of these elements is not possible based on the current data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. As such, these aspects cannot be detailed in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is March 1, 2024, with an anticipated end date of May 31, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in relevant biomarkers or symptom improvement. The schedule for measuring and collecting data is typically aligned with the trial's timeline, ensuring systematic data collection at predefined intervals. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the potential therapeutic effects of the investigational product. The trial's design and methodology adhere to regulatory standards to ensure the reliability and validity of the findings.